1-5 of 5
Nikolay Tzvetkov, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Sebastian Grosicki, MD PhD, Genadi Iosava, MD, Mamia Zodelava, MD, Nikolay Tzvetkov, MD, Tadeusz Robak, MDPhD, Atanas Radinoff, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25.
https://doi.org/10.1182/blood-2020-136031
Published: 2020
Journal Articles

Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia

Jean Jacques Kiladjian, MD PhD, Uwe Platzbecker, Jiri Mayer, MD, Árpád Illés, MD PhD, Witold Prejzner, MD PhD, Tomasz Wozny, MD PhD, Nikolay Tzvetkov, MD, Alessandro M. Vannucchi, MD, Ilya Kirgner, MD, Zsolt Nagy, MD PhD, Sebastian Grosicki, MD PhD, Åsa Rangert Derolf, MDPhD, Mihaela Lazaroiu, MD, Sung-Soo Yoon, MD PhD, Yeow Tee Goh, MBBS, Nikolas Von Bubnoff, Srdan Verstovsek, MD PhD, Barbara Jane Klencke, MD, Rafe Donahue, PhD, Ruben Mesa, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-135880
Published: 2020
Journal Articles

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

David J. Kuter, Ralph V. Boccia, MD, Eun-Ju Lee, MD, Merlin Efraim, MD, Nikolay Tzvetkov, MD, Jiri Mayer, MD, Marek Trněný, MD, Milan Kostal, MD, Roman Hajek, MD, Vickie McDonald, MD, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 87.
https://doi.org/10.1182/blood-2019-122336
Published: 2019
Journal Articles

CELSG CML 11 “ISTAHIT” Phase III Study – Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph + /BCR-ABL + CML Patients in Chronic Phase.

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominic Fong, MD, Thomas Lion, MD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Stefan Goranov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Radka Oucheva, MD, Hanno Ulmer, PhD, Marthin Kwakkelstein, MD, Gianluca Fincato, MD, Guenther Gastl, MD
Journal: Blood
Blood (2008) 112 (11): 1112.
https://doi.org/10.1182/blood.V112.11.1112.1112
Published: 2008
Journal Articles

Multicenter, Randomized, Phase III Study Comparing Imatinib (Glivec) Standard Dose (400 mg/d) with Imatinib High Dose Induction (800 mg/d) Followed by Imatinib Maintenance (400 mg/d) in Patients with Pretreated Ph + /BCR-ABL + CML in Chronic Phase - Results from the First Planned Interim Analysis (CELSG-CML 11 ISTAHIT Study).

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominik Fong, MD, Thomas Lion, MD, PhD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Emil Spasov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Atanas Stanchev, MD, Martin Kwakkelstein, MD, Hanno Ulmer, PhD, Guenther A. Gastl, MD
Journal: Blood
Blood (2007) 110 (11): 1048.
https://doi.org/10.1182/blood.V110.11.1048.1048
Published: 2007